These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33048621)

  • 21. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
    Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nodal Recurrence From Prostate Adenocarcinoma: Curable or Incurable?
    Rodríguez-López JL; Beriwal S
    Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):236-237. PubMed ID: 31928636
    [No Abstract]   [Full Text] [Related]  

  • 23. ACR Appropriateness Criteria
    ; Froemming AT; Verma S; Eberhardt SC; Oto A; Alexander LF; Allen BC; Coakley FV; Davis BJ; Fulgham PF; Hosseinzadeh K; Porter C; Sahni VA; Schuster DM; Showalter TN; Venkatesan AM; Wang CL; Remer EM
    J Am Coll Radiol; 2018 May; 15(5S):S132-S149. PubMed ID: 29724417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incorporating imaging into personalized medicine for the detection of prostate cancer: Pharmacological research-Urogenital pharmacology.
    Mertan F; Turkbey B
    Pharmacol Res; 2016 Dec; 114():163-165. PubMed ID: 27777131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications.
    Hope TA; Afshar-Oromieh A; Eiber M; Emmett L; Fendler WP; Lawhn-Heath C; Rowe SP
    AJR Am J Roentgenol; 2018 Aug; 211(2):286-294. PubMed ID: 29949419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate cancer update.
    Rosenberg J; Small EJ
    Curr Opin Oncol; 2003 May; 15(3):217-21. PubMed ID: 12778015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer.
    Drangsholt S; Walter D; Ciprut S; Lepor A; Sedlander E; Curnyn C; Loeb S; Malloy P; Winn AN; Makarov DV
    Urol Oncol; 2019 Feb; 37(2):145-149. PubMed ID: 30578160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer.
    Huncharek M; Muscat J
    Cancer Invest; 1995; 13(1):31-5. PubMed ID: 7530590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gallium-68-prostate-specific membrane antigen (
    van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
    BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of stage A1 prostate cancer: the case for treatment.
    Bahnson RR
    Semin Urol; 1993 May; 11(2):54-7. PubMed ID: 7689739
    [No Abstract]   [Full Text] [Related]  

  • 31. [Imaging of locally advanced prostate cancer : Importance of ultrasound and especially MRI].
    Solyanik O; Schlenker B; Gratzke C; Ertl-Wagner B; Clevert DA; Stief C; Ricke J; Nörenberg D
    Urologe A; 2017 Nov; 56(11):1383-1393. PubMed ID: 28986612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relapsing Prostate Cancer: Castrate or Cure?
    Tharmalingam H; Choudhury A
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1095-1096. PubMed ID: 29722651
    [No Abstract]   [Full Text] [Related]  

  • 33. Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.
    Siva S; Udovicich C; Tran B; Zargar H; Murphy DG; Hofman MS
    Nat Rev Urol; 2020 Feb; 17(2):107-118. PubMed ID: 31937920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Magnetic resonance imaging facilitate appropriate treatment selection of prostate cancer patients].
    Boesen L; Thomsen HS
    Ugeskr Laeger; 2013 Jun; 175(23):1634-7. PubMed ID: 23731990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer.
    Huncharek M; Muscat J
    Abdom Imaging; 1996; 21(4):364-7. PubMed ID: 8661585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Multimodality MRI and PET for restaging prostate cancer after biochemical failure of the treatment].
    Cochet A; Kanoun S; Humbert O; Walker PM; Cormier L; Créhange G; Brunotte F
    Cancer Radiother; 2014 Oct; 18(5-6):509-16. PubMed ID: 25195114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer.
    Jadvar H
    Abdom Radiol (NY); 2016 May; 41(5):889-98. PubMed ID: 27193789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
    Kuten J; Mabjeesh NJ; Lerman H; Levine C; Barnes S; Even-Sapir E
    Isr Med Assoc J; 2019 Feb; 21(2):100-104. PubMed ID: 30772960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Capromab Pendetide imaging of prostate cancer.
    Haseman MK; Rosenthal SA; Polascik TJ
    Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.